Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Hypersensitivity pneumonitis
Clinical narrative: diagnose with hypersensitivity pneumonitis; This spontaneous case was reported by a patient and describes the occurrence of HYPERSENSITIVITY PNEUMONITIS (diagnose with hypersensitivity pneumonitis) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Patient has no medical history relating to mentioned adverse event and both acute and chronic illnesses at the time of vaccination.  Patient has no allergies.  The patient never had COVID positive test or diagnosis.  The patient's past medical history included Shortness of breath (Occasional). Concomitant products included TRAZODONE for an unknown indication.   In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HYPERSENSITIVITY PNEUMONITIS (diagnose with hypersensitivity pneumonitis) (seriousness criteria hospitalization and medically significant). The patient was hospitalized for 7 days due to HYPERSENSITIVITY PNEUMONITIS. The patient was treated with PREDNISONE for Hypersensitivity pneumonitis, at an unspecified dose and frequency. At the time of the report, HYPERSENSITIVITY PNEUMONITIS (diagnose with hypersensitivity pneumonitis) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No other vaccines given within 1 month prior to Moderna COVID-19 vaccine. It was reported that 5 days after getting their first dose of the moderna covid-19 vaccine on Mar-2021 later had severe inflammation of the lung, was in hospital for a week and had a biopsy. Also mentioned lungs swell up and it took a year to recover. It was mentioned that got the second dose 28 days after the first dose.  Company comment: This spontaneous case concerns a 39-year-old male patient who received 2 doses of mRNA-1273 vaccine with an interval of 28 days, and experienced medically significant event of hypersensitivity pneumonitis after receiving the first dose. Patient stated that 5 days after getting the first dose in Mar-2021, he had severe inflammation of  the lung, was in hospital for a week, had a biopsy, and was treated with prednisone. It took a year to recover. Relevant medical history included occasional shortness of breath. No further details regarding clinical course, diagnostic tests or treatment performed were disclosed. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 39-year-old male patient who received 2 doses of mRNA-1273 vaccine with an interval of 28 days, and experienced medically significant event of hypersensitivity pneumonitis after receiving the first dose. Patient stated that 5 days after getting the first dose in Mar-2021, he had severe inflammation of  the lung, was in hospital for a week, had a biopsy, and was treated with prednisone. It took a year to recover. Relevant medical history included occasional shortness of breath. No further details regarding clinical course, diagnostic tests or treatment performed were disclosed. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.